Supernus Pharmaceuticals, Inc. (SUPN) — Analysis Summary
Supernus Pharmaceuticals, Inc. (SUPN) has a market cap of $2.59B with year-over-year revenue growth of +8.6%. Net margin stands at -5.4%. The stock trades at a P/E ratio of -89.3.
Key Takeaways
- Revenue changed +8.6% year-over-year
- Net margin of -5.4%
- P/E ratio of -89.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SUPN posted revenue growth of +8.6% and trades at a P/E of -89.3.
Supernus Pharmaceuticals, Inc. (SUPN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
778
Headquarters
ROCKVILLE, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.